ONKOLOGY AT LENBACHPLATZ
​
​
​
Philosophy
​
Today as a specialist in internal medicine, haematology and oncology, for me personally the most important thing is if after the interview or the visit the patient says that they finally feel "on top" again, that just as before, the therapy or even the disease doesn't determine everything, but people feel able to trust their own life again. In such moments, I see the possibility of being able to "feel again" and "to go one's own way."
Cancer is a so-called multimodal disease. That is, it usually does not require just a single event to cause malignant tumour manifestation. Here there are aspects such as genetic disposition, smoking, nutrition, stress, overweight, environmental toxins, interference, reduced movement, etc.
It is all the more important that the therapy is accordingly multimodal, even holistic. From my point of view, we can only live up to this claim if we work in a therapeutic team or in a healthy network in which the different strengths of the individual combine to form a synergistic whole. Everything else carries the danger of a monocausal or outdated therapeutic structure, as is currently
still too often the case, and unfortunately the disease is definitely not up to cancer and the affected patients.
In particular, for chronic and complex diseases such as cancer, a healthy communication between doctor and patient is the ultimate goal, in order to support the patient in the development of his autonomy as much as possible. This is only possible at eye level and not "from above". To do this, we must signal to the patient right from the start that we are not only working "against" symptoms, but that the therapist relies on the active cooperation of the patient. Thus the patient can be given the space for growing awareness and autonomous self-regulation; this can bring multimodal to holistic concepts to life.
For me, this is the most exciting thing about my therapeutic work: Through a steadily growing self-determination in the patients, new, possibly previously invisible solutions and ways can be found in the healthy approach method - here, inner well-being and true recovery can take place.
PRIV-DOZ. DR. MED. NILS H. THOENNISSEN
​
​
Professional and
research career
​
"Everyone who goes their own way is a hero.
Everyone who really does and lives that,
what he is capable of, is a hero - and even
if he does something stupid and backward,
he is worth much more than a thousand other people,
who merely speak of their beautiful ideals,
without sacrificing themselves."
Hermann Hesse
Publications
​
State 10/2018:
​
Original articles – First / Last authorship
(chronological order) (*shared first/last authorship)
​
1. Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH*, Berdel WE.Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta Haematol. 2017;137(3):163-172
2. Pohlen M, Thoennissen NH*, Braess J, Thudium J2, Schmid C3, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS One. 2016 Aug 30;11(8):e0160871
3. Karagiannis P, Guth N, Thoennissen GB, Bern C, Sperveslage J, Oschlies I, Bokemeyer, C, Klapper W, Wardelmann E, Thoennissen NH: Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT. Clin Sarcoma Res. 2015; 5: 24.
4. Thoennissen NH, Clauditz T, Ittrich H, Stahl R, Bokemeyer C, Klose H. 55-year old woman, smoking, with obvious exhaustion, fever and hemoptysis. Dtsch Med Wochenschr. 2014 Oct;139(41):2073-4.
5. Bettenworth D, Nowacki TM, Ross M, Kyme P, Schwammbach D, Kerstiens L, Thoennissen GB, Bokemeyer C, Hengst K, Berdel WE, Heidemann J, Thoennissen NH. Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance. Mol Nutr Food Res. 2014;58(7):1474-90.
6. Hascher A, Haase AK, Hebestreit K, Rohde C, Klein HU, Rius M, Jungen D, Witten A, Stoll M, Schulze I, Ogawa S, Wiewrodt R, Tickenbrock L, Berdel WE, Dugas M, Thoennissen NH*, Müller-Tidow C. DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res. 2014 Feb 15;20(4):814-26.
7. Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller- Tidow C, Berdel WE, Thoennissen NH. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013 Aug;92(8):1041-48.
8. Kyme P, Thoennissen NH*, Tseng CW, Thoennissen GB, Wolf AJ, Shimada K, Krug UO, Lee K, Müller-Tidow C, Berdel WE, Hardy WD, Gombart AF, Koeffler HP, Liu GY. C/EBPεmediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. J Clin Invest. 2012 Sep 4;122(9):3316-29.
9. Thoennissen GB, Thoennissen NH*, Fritz F, Hilbig A, Kerkhoff A, Liersch R, Krug U, Koschmieder S, Müller-Tidow C, Mesters R, Kropff M, Berdel WE. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. Ann. Hematol. 2012 Sep;91(9):1419-25.
10. Thoennissen NH, Thoennissen GB, Nabavi-Nouis S, Abbassi S, Sauer T, Doan NB, Gery S, Müller-Tidow C, Said JW, Koeffler HP. The transcription factor C/EBPalpha and a critical circadian clock downstream target gene, PER2, are highly deregulated in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Aug;53(8):1577-85.
11. Thoennissen NH, Lasho T, Thoennissen GB, Ogawa S, Tefferi A, Koeffler HP. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol. 2011;86(8):703-05.
12. Lee DH, Thoennissen NH*, Goff C, Iwanski GB, Forscher C, Doan NB, Said JW, Koeffler HP. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett. 2011 Jul 28;306(2):161-70.
13. Akagi T, Thoennissen NH*, George A, Crooks G, Song JH, Okamoto R, Nowak D, Gombart AF, Koeffler HP. In Vivo Deficiency of Both C/EBPβand C/EBPεResults in Highly Defective Myeloid Differentiation and Lack of Cytokine Response. PLoS One. 2010;5(11):e15419.
14. Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH*, Koeffler HP. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol. 2010;160(4):998-1007
15. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115(14):2882-90.
16. Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, Karlan B, Mehta R, Koeffler HP. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene. 2010;29(2):285-96.
17. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009;69(14):5876-84.
18. Thoennissen NH, Keyvani K, Voelker HU, Bremer J, Krug U, Müller-Tidow C, Koch P, Müller-Hermelink HK, Berdel WE. Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation. J Clin Oncol. 2008;26(27):4509-11.
19. Thoennissen NH, Schliemann C, Hungermann D, Bremer J, Juergens KU, Semik M, Müller-Tidow C, Zuehlsdorf M, Berdel WE. Solitary plasmacytoma of the lung with coexisting sarcoid-like lesions. Ann Hematol. 2008;87(5):417-20.
20. Thoennissen NH, Schliemann C, Brunnberg U, Schmidt E, Staebler A, Stegger L, Bremer C, Schleicher C, Mesters RM, Müller-Tidow C, Berdel WE. Chemotherapy in metastatic malignant triton tumor: report on two cases. Oncol Rep. 2007;18(4):763-67.
21. Thoennissen NH, Baumann C, Kelsch R, Albrecht O, Müller-Tidow C, Sibrowski W, Berdel WE, Mesters R: Heparin-Induced Thrombocytopenia vs. Plasmapheresis-Induced Platelet Loss in a Case of Thrombotic Thrombocytopenic Purpura. Transfusion Medicine and Hemotherapy. 2007;34:74-77.
22. Thoennissen NH, Allroggen A, Ritter M, Dittrich R, Schmid C, Schmid HH, Ringelstein EB, Nabavi DG. Influence of inflammation and pump dynamic on cerebral microembolization in patients with Continuous-Flow DeBakey LVAD. ASAIO J. 2006;52(3):243-47.
23. Thoennissen NH, Schneider M, Allroggen A, Ritter M, Dittrich R, Schmid C, Scheld HH, Ringelstein EB, Nabavi DG. High level of cerebral microembolization in patients supported with the DeBakey left ventricular assist device. J Thorac Cardiovasc Surg. 2005;130(4):1159-66.
24. Thoennissen NH, Allroggen A, Dittrich R, Ritter M, Schmid C, Scheld HH, Ringelstein EB, Nabavi DG. Can Doppler time domain analysis of microembolic signals discriminate between gaseous and solid microemboli in patients with left ventricular assist device? Neurol Res. 2005;27(7):780-84.
Original articles - Co-authorship:
(chronological order)
1. Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow CM, Berdel WE and Arteaga MF. Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer. Eur Respir J. 2018 May 31. pii: 1701637.
2. Bulk E, Ay AS, Hammadi M, Schölhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Klein HU, Dugas M, Berdel WE, Müller-Tidow C, Schwab A. Epigenetic dysregulation of Kca 3.1 channels induces poor prognosis in lung cancer. Intern J Cancer. 2015;137(6):1306-17.
3. Nowak D, Liem NLM, Mossner M, Papa RA, Nowak V, Jann JC, Kawamata N, Okamoto R, Thoennissen NH, Kato M, Hofmann WK, Ogawa S, Lock RB, Koeffler HP. Variegated clonality and rapid emergence of new molecular lesions in xenograftsof acute lymphoblastic leukemia are associated with drug resistance. Exp Hematol. 2015;43(1):32-43.
4. Nowacki TM, Brückner M, Tepasse P, Pott F, Thoennissen NH, Hengst K, Ross M, Bettenworth D. The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Science, 2015;60(2):492-501.
5. Kanda J, Mori K, Kawabata H, Kuwabara T, Mori KP, Imamaki H, Kasahara M, Yokoi H, Mizumoto C, Thoennissen NH, Koeffler HP, Barasch J, Takaori-Kondo A, Mukoyama M, Nakao K. An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. Clin Exp Nephrol. 2015;19(1):99- 106.
6. Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoennissen NH, Huge A, Voss R, Marra A, Faldum A, Müller-Tidow C, Berdel WE, Wiewrodt R. Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression of MALAT-1 lncRNA in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014;9(9):1294-304
7. Evers G, Pohlen M, Berdel WE, Thoennissen NH, Titze U, Köhler G, Weckesser M, Anthoni C, Mesters RM. Visceral leishmaniasis clinically mimicking lymphoma. Ann Hematol.2014;93(5):885-7.
8. Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW, Koeffler HP. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer. 2013;132(12):2730-37.
9. Gerth HU, Pohlen M, Thoennissen NH, Suwelack B, Pavenstädt HJ, Störkel S, Abbas M, Spieker T, Thölking G. Two papillary renal cell carcinomas of different origin following renal transplantation. Oncol Lett. 2012;4(1):80-82.
10. Agrawal-Singh S, Isken F, Agelopoulos K, Klein HU, Thoennissen NH, Koehler G, Hascher A, Baeumer N, Berdel WE, Thiede C, Ehninger G, Becker A, Schlenke P, Wang Y, McClelland M, Krug U, Koschmieder S, Buechner T, Yu DY, Singh SV, Hansen K, Serve H, Dugas M, Mueller-Tidow C. Genome wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012;119(10):2346-57.
11. Müller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen NH, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, Zur Stadt U, Koschmieder S, Seidl M, Müller FU, Schmitz W, Schlenke P, McClelland M, Berdel WE, Dugas M, Serve H; on behalf of the Study Alliance Leukemia. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood. 2010;116(18):3564-71.
12. Agrawal-Singh S, Koschmieder S, Gelsing S, Stocking C, Stehling M, Thiede C, Thoennissen NH, Köhler G, Valk PJ, Delwel R, Mills K, Bäumer N, Tickenbrock L, Hansen K, Berdel WE, Müller-Tidow C, Serve H. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model. Blood. 2010;115(22):4507-16.
13. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010;115(5):1049-53.
14. Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, Zühlsdorf M, Müller-Tidow C, Berdel WE. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol. 2008;19(9):1644-49.
15. Schliemann C, Bieker R, Thoennissen NH, Gerss J, Liersch R, Kessler T, Büchner T, Berdel WE, Mesters RM. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia. 2007;21(9):1901-06.
16. Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, Zühlsdorf M, Berdel WE, Mesters RM. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia. 2007;21(6):1310-12.
​
17. Kleef R, Nagy R, Baierl A, Bacher V, Bojar H, McKee DL, Moss R, Thoennissen NH, Szász M, Bakacs T. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution. Cancer Immunol Immunother. 2020 Nov 5.
Reviews:
(chronological order)
Thoennissen NH, Koeffler HP. Leukaemic Transformation of Philadelphia-chromosome negative Myeloproliferative Neoplasms - A Review of the Molecular Background. European Oncology & Haematology, 2011;7(1):59-62
Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal. 2010;10:413-18.
Ritter MA, Dittrich R, Thoennissen NH, Ringelstein EB, Nabavi DG: Prevalence and prognostic impact of microembolic signals in arterial sources of embolism: A systematic review of the literature. Journal of Neurology. 2008;255(7):953-61.
Book chapter:
Iwanski GB, Thoennissen NH, Tavor S, Koeffler HP. Therapy-related Acute Myelogenous Leukemia. Neoplastic Diseases of the Blood, 2013 Dec; 5th Edition; page 455-486 Cambridge University Press Springer Science & Business Media, New York 2013
2018
Medical Manager
Day Clinic - CBC Health Med Munich
Private Practice - onkologie at Lenbachplatz
Ottostr. 3
D-80333 München
2017 – 2018
Head Doctor
St. Georg Clinic, Bavaria
2015 – 2017
Head Doctor
Kloster Paradiese Clinic, NRW
2014 – 2015
Senior Physician
II. Med. Clinic and Polyclinic
Oncology, Haematology with the section Pneumology
University Hospital Hamburg-Eppendorf
Head of the scientific working group
Epigenetic in Cancer and Infection
University Hospital Hamburg-Eppendorf
Senior Physician intern. Emergency department
University Hospital Hamburg-Eppendorf
2013
Specialist in internal medicine, haematology & oncology
University Hospital Münster
2013
Venia legendi for internal medicine
Westfälische Wilhelms-Universität Münster
2012
Habilitation and venia legendi experimental haematology:
"Analyses of the importance of molecular and clinical changes
for the development, progression and prognosis of acute myeloid leukaemia "
Westfälische Wilhelms-Universität Münster
2010
IZKF Research Fellowship
University Hospital Münster
2008 – 2010
DFG Foreign Research Fellowship as a postdoctoral fellow
Division of Haematology/Oncology, Prof. H. Phillip Koeffler
Cedars-Sinai Medical Center, UCLA Los Angeles, USA
2007
IZKF Research Fellowship
University Hospital Münster
2005 – 2007
Assistant physician
Internal Medicine A - Haematology/Oncology
University Hospital Münster
06/2005
PhD summa cum laude
"Detection of microembolic signals by transcranial
Doppler sonography in patients with artificial
left ventricular contraction replacement type DeBakey"
Westfälische Wilhelms Universität, Münster
1999 – 2005
Medical studies
-
Westfälische Wilhelms-Universität Münster
-
Cardiff University School of Medicine, Wales, UK
-
Johannes Gutenberg Universität, Mainz
1996 – 1999
Nursing
Municipal Clinic Cologne